Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 3, 2013, Pages 515-528

  Semiond D ^a   Sidhu, S S ^a   Bissery, M C ^a,b   Vrignaud, P ^a  

^a SANOFI   (France)

^b Genticel   (France)

Author keywords

Cabazitaxel (RPR 116258A, XRP6258, TXD258); Central nervous system; Docetaxel; Pediatrics; Sarcomas; Xenografts

Indexed keywords

CABAZITAXEL; CISPLATIN; DOCETAXEL; RPR 166258A; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILD HEALTH CARE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG SCREENING; EARLY CANCER; EWING SARCOMA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIOACTIVITY; RAT; RHABDOMYOSARCOMA; SARCOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CHILD, PRESCHOOL; CISPLATIN; DOGS; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM STAGING; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TAXOIDS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84883487922     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2214-x     Document Type: Article

References (43)

1. Harrison MR, Holen KD, Liu G (2009) Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 7:54-64
2. Deeken JF, Loscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663-1674
3. Agarwal S, Hartz AM, Elmquist WF, Bauer B (2011) Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 17:2793-2802
4. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G (2002) Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309-1318
5. Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O (2004) Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 40:1269-1274
6. Prados MD, Schold SC, Spence AM, Berger MS, McAllister LD, Mehta MP, Gilbert MR, Fulton D, Kuhn J, Lamborn K, Rector DJ, Chang SM (1996) Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14:2316-2321
7. Chamberlain MC, Kormanik P (1995) Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13:2066-2071
8. Chamberlain MC, Kormanik P (1999) Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J Neurooncol 43:71-78
9. Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R (2001) Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol 23:277-281
10. Forsyth P, Cairncross G, Stewart D, Goodyear M, Wainman N, Eisenhauer E (1996) Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 14:203-206
11. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, Hadani M, Ram Z (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100:472-479
12. Izbicka E, Campos D, Marty J, Carrizales G, Mangold G, Tolcher A (2006) Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models. Anticancer Res 26:1983-1988
13. Blaney SM, Seibel NL, O'Brien M, Reaman GH, Berg SL, Adamson PC, Poplack DG, Krailo MD, Mosher R, Balis FM (1997) Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol 15:1538-1543
14. Hurwitz CA, Relling MV, Weitman SD, Ravindranath Y, Vietti TJ, Strother DR, Ragab AH, Pratt CB (1993) Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 11:2324-2329
15. Zwerdling T, Krailo M, Monteleone P, Byrd R, Sato J, Dunaway R, Seibel N, Chen Z, Strain J, Reaman G (2006) Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Cancer 106:1821-1828
16. Mora J, Cruz CO, Parareda A, de Torres C (2009) Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 31:723-729
17. Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, Smykla R, Lee FYF, Houghton PJ (2005) In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 11:6950-6958
18. Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC (2010) Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res 16:750-754
19. ® (cabazitaxel) Injection. Summary of Product Characteristics, EMA
20. ® (cabazitaxel) Injection. Prescribing Information, FDA
21. Mita AC, Denis LJ, Rowinsky EK, de Bono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15:723-730
22. Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, Riou J-F, Commerçon A, Lavelle F, Bissery M-C (2013) Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 19:2973-2983
23. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM (2003) Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 138:1367-1375
24. Carrle D, Bielack SS (2006) Current strategies of chemotherapy in osteosarcoma. Int Orthop 30:445-451
25. Jekunen AP, Christen RD, Shalinsky DR, Howell SB (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69:299-306
26. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP Jr, Schabel FM Jr (1982) Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res 42:1707-1715
27. Geran R, Greenberg N, Macdonald M, Schumacher A, Abbott B (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep 3:1-103
28. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44:717-726
29. Bissery MC, Vrignaud P, Lavelle F (1995) Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Semin Oncol 22:3-16
30. Dieras V, Lortholary A, Laurence V, Delva R, Girre V, Livartowski A, Assadourian S, Semiond D, Pierga JY (2013) Cabazitaxel in patients with advanced solid tumours: results of a phase I and pharmacokinetic study. Eur J Cancer 49:25-34
31. ® (carmustine for injection). Prescribing Information, FDA
32. Roche VF (2012) Cancer and chemotherapy. In: Lemke TL, Williams DA (eds) Foye's principles of medicinal chemistry. Lippincott, Williams & Wilkins, Philadelphia, PA, USA
33. O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM (2008) Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 62:1045-1054
34. Oehler C, Frei K, Rushing EJ, McSheehy PM, Weber D, Allegrini PR, Weniger D, Lutolf UM, Knuth A, Yonekawa Y, Barath K, Broggini-Tenzer A, Pruschy M, Hofer S (2012) Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology 83:1-9
35. Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, Hofmann B, Klar U (2009) Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 11:158-166
36. Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, Krop IE, Partridge AH, Eisenberg E, Winer EP, Lin NU (2011) A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer 11:376-383
37. Stupp R, Tosoni A, Bromberg JE, Hau P, Campone M, Gijtenbeek J, Frenay M, Breimer L, Wiesinger H, Allgeier A, van den Bent MJ, Bogdahn U, van der Graaf W, Yun HJ, Gorlia T, Lacombe D, Brandes AA (2011) Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol 22:2144-2149
38. Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS (2011) Challenging issues in pediatric oncology. Nat Rev Clin Oncol 8:540-549
39. Burningham Z, Hashibe M, Spector L, Schiffman JD (2012) The epidemiology of sarcoma. Clin Sarcoma Res 2:14
40. Kopetz S, Lemos R, Powis G (2012) The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 18:5160-5162
41. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierre A, De The H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prevost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18:5314-5328
42. Stordal B, Davey M (2007) Understanding cisplatin resistance using cellular models. IUBMB Life 59:696-699
43. Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami N, Modjtahedi N, Harel-Bellan A, Kroemer G (2008) Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 27:4221-4232